Miriam Mutebi, Breast Surgical Oncologist, shared on LinkedIn:
“What if we expanded our definition of innovation?
We’ve made remarkable advances in understanding breast cancer biology, diagnostics and treatment. New therapies continue to transform what is possible for women diagnosed with breast cancer.
But scientific progress does not automatically translate into better outcomes for every woman.
A breakthrough treatment may be highly effective, but its impact depends on whether a woman can access timely diagnosis, appropriate testing, affordable treatment, and coordinated care.
Between discovery and delivery lie the systems, processes and people that determine whether innovation actually makes a difference.
This is the central argument of my Comment, ‘Making breast cancer innovation deliver for every woman,’ featured in the November issue of Nature Reviews Cancer.
I believe we need to broaden what we recognise and invest in as innovation.
Shorter treatment regimens, simplified diagnostics, more affordable therapies, better referral pathways and more reliable coordination of care may not always attract the same attention as the latest scientific breakthrough.
Yet these advances can be just as consequential in determining who benefits from progress.
We need continued scientific discovery alongside innovation in how we organise, finance and deliver care. The two must evolve together.
Perhaps we need to ask not only what new things medicine can do, but what we can make possible for more women.
Because the promise of innovation lies not only in what we discover, but in what we deliver.
Title: Making breast cancer innovation deliver for every woman
Authors: Miriam Mutebi
You may also be interested in: Olivia Munn and Mark Kelly Introduce Know Your Risk Act for Breast Cancer
